Toronto Dominion Bank Sells 35,828 Shares of Novo Nordisk A/S (NYSE:NVO)
Toronto Dominion Bank lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 63.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,055 shares of the company’s stock after selling 35,828 shares during the period. Toronto Dominion Bank’s holdings in Novo Nordisk A/S were worth $1,075,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in NVO. Advisors Preferred LLC bought a new stake in Novo Nordisk A/S in the 2nd quarter valued at approximately $26,000. TCG Advisors LP bought a new stake in Novo Nordisk A/S in the 1st quarter valued at approximately $27,000. Valeo Financial Advisors LLC lifted its stake in Novo Nordisk A/S by 510.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock valued at $32,000 after acquiring an additional 526 shares in the last quarter. Wealthcare Advisory Partners LLC lifted its stake in Novo Nordisk A/S by 75.6% in the 2nd quarter. Wealthcare Advisory Partners LLC now owns 864 shares of the company’s stock valued at $44,000 after acquiring an additional 372 shares in the last quarter. Finally, Meridian Wealth Management LLC bought a new stake in Novo Nordisk A/S in the 1st quarter valued at approximately $48,000. Institutional investors and hedge funds own 7.34% of the company’s stock.
NYSE NVO traded down $0.19 on Wednesday, reaching $51.31. The stock had a trading volume of 8,710 shares, compared to its average volume of 1,432,759. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.04 and a quick ratio of 0.73. The firm has a fifty day moving average of $51.72 and a two-hundred day moving average of $50.11. Novo Nordisk A/S has a 1-year low of $41.23 and a 1-year high of $53.55. The company has a market cap of $121.50 billion, a P/E ratio of 20.39, a price-to-earnings-growth ratio of 2.17 and a beta of 0.58.
Several equities research analysts have commented on NVO shares. Deutsche Bank cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 target price on the stock. in a research note on Thursday, June 20th. Bank of America upped their price objective on Novo Nordisk A/S from $355.00 to $400.00 and gave the stock a “neutral” rating in a research note on Friday, September 13th. ValuEngine lowered Novo Nordisk A/S from a “sell” rating to a “strong sell” rating in a report on Saturday. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 target price on the stock in a report on Monday, July 15th. Finally, Barclays raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 target price on the stock in a report on Tuesday, June 11th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $159.65.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
See Also: Limitations of the P/E Growth ratio
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.